2018 Peptic Ulcers Drug Development- Pipeline Analysis Report
Atleast 10% of US population suffers from peptic ulcers in a lifetime. The serious condition observes ulcers in stomach and beginning of small intestine or lining of the esophagus. The market value is estimated to be around half billion USD in 2020. In particular, aged popultion and female gender are more susceptible to the disease.
Over 20 companies and universities are focusing on developing treatment options for Peptic Ulcers.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Peptic Ulcers pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Peptic Ulcers pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peptic Ulcers pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 20 companies and universities are focusing on developing treatment options for Peptic Ulcers.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Peptic Ulcers pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Peptic Ulcers pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peptic Ulcers pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 PEPTIC ULCERS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peptic Ulcers Pipeline Snapshot
2.3 Peptic Ulcers Pipeline by Phase
2.4 Peptic Ulcers Pipeline by Company
2.5 Peptic Ulcers Pipeline by Mechanism of Action
3 PEPTIC ULCERS- COMPANY WISE PIPELINE ANALYSIS
Balto Therapeutics, LLC
Boryung Pharmaceutical Co., Ltd
Catalent, Inc.
CJ HealthCare Corp.
Daewoong Pharmaceutical Co., Ltd
Infectex Ltd
Kukje Pharmaceutical Company
Pfizer, Inc.
Pharmaking Ltd
PT. Dexa Medica
RaQualia Pharma Inc.
Recce Pharmaceuticals Ltd
Sequella Inc
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Sihuan Pharmaceutical Holdings Group
Sinil Pharmaceutical Co., Ltd
Xuanzhu Pharma Co Ltd
4 PEPTIC ULCERS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PEPTIC ULCERS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 PEPTIC ULCERS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peptic Ulcers Pipeline Snapshot
2.3 Peptic Ulcers Pipeline by Phase
2.4 Peptic Ulcers Pipeline by Company
2.5 Peptic Ulcers Pipeline by Mechanism of Action
3 PEPTIC ULCERS- COMPANY WISE PIPELINE ANALYSIS
Balto Therapeutics, LLC
Boryung Pharmaceutical Co., Ltd
Catalent, Inc.
CJ HealthCare Corp.
Daewoong Pharmaceutical Co., Ltd
Infectex Ltd
Kukje Pharmaceutical Company
Pfizer, Inc.
Pharmaking Ltd
PT. Dexa Medica
RaQualia Pharma Inc.
Recce Pharmaceuticals Ltd
Sequella Inc
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Sihuan Pharmaceutical Holdings Group
Sinil Pharmaceutical Co., Ltd
Xuanzhu Pharma Co Ltd
4 PEPTIC ULCERS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PEPTIC ULCERS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Peptic Ulcers Pipeline by Phase, H1- 2018
Figure 2: Peptic Ulcers Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Peptic Ulcers Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Peptic Ulcers Pipeline by Phase, H1- 2018
Figure 2: Peptic Ulcers Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Peptic Ulcers Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Peptic Ulcers Pipeline by Phase, H1- 2018
Table 2: Peptic Ulcers Pipeline by Companies, H1- 2018
Table 3: Peptic Ulcers Pipeline by Mechanism of Action, H1- 2018
Table 4: Balto Therapeutics, LLC Peptic Ulcers Pipeline, May 2018
Table 5: Boryung Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 6: Catalent, Inc. Peptic Ulcers Pipeline, May 2018
Table 7: CJ HealthCare Corp. Peptic Ulcers Pipeline, May 2018
Table 8: Daewoong Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 9: Infectex Ltd Peptic Ulcers Pipeline, May 2018
Table 10: Kukje Pharmaceutical Company Peptic Ulcers Pipeline, May 2018
Table 11: Pfizer, Inc. Peptic Ulcers Pipeline, May 2018
Table 12: Pharmaking Ltd Peptic Ulcers Pipeline, May 2018
Table 13: PT. Dexa Medica Peptic Ulcers Pipeline, May 2018
Table 14: RaQualia Pharma Inc. Peptic Ulcers Pipeline, May 2018
Table 15: Recce Pharmaceuticals Ltd Peptic Ulcers Pipeline, May 2018
Table 16: Sequella Inc Peptic Ulcers Pipeline, May 2018
Table 17: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Peptic Ulcers Pipeline, May 2018
Table 18: Sihuan Pharmaceutical Holdings Group Peptic Ulcers Pipeline, May 2018
Table 19: Sinil Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 20: Xuanzhu Pharma Co Ltd Peptic Ulcers Pipeline, May 2018
Table 1: Peptic Ulcers Pipeline by Phase, H1- 2018
Table 2: Peptic Ulcers Pipeline by Companies, H1- 2018
Table 3: Peptic Ulcers Pipeline by Mechanism of Action, H1- 2018
Table 4: Balto Therapeutics, LLC Peptic Ulcers Pipeline, May 2018
Table 5: Boryung Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 6: Catalent, Inc. Peptic Ulcers Pipeline, May 2018
Table 7: CJ HealthCare Corp. Peptic Ulcers Pipeline, May 2018
Table 8: Daewoong Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 9: Infectex Ltd Peptic Ulcers Pipeline, May 2018
Table 10: Kukje Pharmaceutical Company Peptic Ulcers Pipeline, May 2018
Table 11: Pfizer, Inc. Peptic Ulcers Pipeline, May 2018
Table 12: Pharmaking Ltd Peptic Ulcers Pipeline, May 2018
Table 13: PT. Dexa Medica Peptic Ulcers Pipeline, May 2018
Table 14: RaQualia Pharma Inc. Peptic Ulcers Pipeline, May 2018
Table 15: Recce Pharmaceuticals Ltd Peptic Ulcers Pipeline, May 2018
Table 16: Sequella Inc Peptic Ulcers Pipeline, May 2018
Table 17: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Peptic Ulcers Pipeline, May 2018
Table 18: Sihuan Pharmaceutical Holdings Group Peptic Ulcers Pipeline, May 2018
Table 19: Sinil Pharmaceutical Co., Ltd Peptic Ulcers Pipeline, May 2018
Table 20: Xuanzhu Pharma Co Ltd Peptic Ulcers Pipeline, May 2018
